Amylyx Pharmaceuticals, Inc.
AMLX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$28.30
KIRA · Stoqly’s AI analyst, in plain words
- Amylyx Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Amylyx Pharmaceuticals, Inc. lost $145M in fiscal 2025.
- Free cash flow was −$123M in fiscal 2025, — of revenue.
Market cap
$3.1B
P/E
—
Revenue
$0.0M
Net income
−$145M
Free cash flow
−$123M
Operating margin
—
Amylyx Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$145M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Amylyx Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Amylyx Pharmaceuticals, Inc.
- CIK
- 0001658551
Amylyx Pharmaceuticals, Inc. · AMLX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.3M | $22.2M | $381M | $87.4M | $0.0M |
| Revenue growth | — | 7,700.0% | 1,612.9% | −77.1% | −100.0% |
| Gross margin | — | 86.5% | 93.3% | 93.2% | — |
| Operating margin | −29,013.3% | −905.7% | 10.2% | −360.2% | — |
| Net income | −$87.9M | −$198M | $49.3M | −$302M | −$145M |
| Net margin | −30,853.0% | −892.4% | 12.9% | −345.4% | — |
| Diluted EPS | −$13.35 | −$3.39 | $0.70 | −$4.43 | −$1.53 |
| Cash | |||||
| Cash from operations | −$74.8M | −$180M | $11.9M | −$168M | −$123M |
| Capital expenditure | $0.4M | $2.5M | $1.2M | $0.2M | $0.1M |
| Free cash flow | −$75.2M | −$182M | $10.7M | −$168M | −$123M |
| FCF margin | −26,369.1% | −820.5% | 2.8% | −192.1% | — |
| Share count change | — | 788.1% | 19.7% | −2.6% | 38.8% |
| Debt and strength | |||||
| Cash and short-term investments | $96.1M | $347M | $371M | $177M | $317M |
| Shareholders' equity | −$151M | $341M | $433M | $165M | $305M |
| Current ratio | 6.0x | 8.2x | 5.7x | 6.7x | 14.3x |
| Returns and quality | |||||
| Return on equity | — | −209.4% | 12.7% | −100.9% | −61.6% |
| Return on tangible equity | — | −58.2% | 11.4% | −183.1% | −47.4% |
| Piotroski F-score | — | 4 | 5 | 3 | 3 |
| Altman Z'' | −13.7 | 6.3 | 8.8 | −9.7 | 7.2 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$10.1M
6 insiders
Of sales under plans
14%
$1.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Amylyx Pharmaceuticals, Inc. · AMLX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $28.30 a share, the company is worth $3.1B.
Source: SEC EDGAR XBRL filings (CIK 0001658551). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.